HCP
REGN icon

Hexagon Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Hexagon Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22
Closed -$14K – 1334
2025
Q1 		$14K Sell
22
-7
-24% -$4.82K ﹤0.01% 869
2024
Q4 		$20.7K Buy
29
+8
+38% +$6.71K ﹤0.01% 774
2024
Q3 		$22.1K Buy
21
+8
+62% +$8.9K ﹤0.01% 683
2024
Q2 		$13.7K Sell
13
-8
-38% -$7.75K ﹤0.01% 792
2024
Q1 		$20.2K Buy
21
+11
+110% +$10.5K ﹤0.01% 673
2023
Q4 		$8.78K Hold
10
– – ﹤0.01% 854
2023
Q3 		$8.23K Sell
10
-3
-23% -$2.36K ﹤0.01% 794
2023
Q2 		$9.34K Hold
13
– – ﹤0.01% 763
2023
Q1 		$10.7K Sell
13
-2
-13% -$1.51K ﹤0.01% 716
2022
Q4 		$10.8K Sell
15
-12
-44% -$8.85K ﹤0.01% 710
2022
Q3 		$19K Buy
27
+24
+800% +$15.1K 0.01% 607
2022
Q2 		$2K Buy
+3
New +$1.95K ﹤0.01% 996
2020
Q4 		– Sell
-50
Closed -$27K – 744
2020
Q3 		$27K Buy
+50
New +$30.3K 0.01% 319

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Hexagon Capital Partners's REGN Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 22 shares — an estimated $14K sold.

Hexagon Capital Partners first reported a position in REGN in Q3 2020 and held it in 13 quarters. The position peaked at $27K in Q3 2020. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 22 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $14K.
  • Hexagon Capital Partners first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 13 quarters.
  • Hexagon Capital Partners's Regeneron Pharmaceuticals position peaked at $27K in Q3 2020.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.